CompoAtlas

SAFRAN ÉQUILIBRE PREMIUM (SAFR’INSIDETM)

Food supplement declared in France, decision dated 10 March 2025

SAFRAN ÉQUILIBRE PREMIUM (SAFR’INSIDETM), from MICRO-EQUILIBRE, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Crocus sativus 30 mg per day. None of the rules we check flags an issue with its declared composition.

Brand
not provided
Food business operator placing the product on the market
MICRO-EQUILIBRE
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
1 gélule
Directions for use
Prendre 1 gélules par jour ou comme conseillé. Vous avez des difficultés à avaler les gélules ? Il est possible de les ouvrir et verser le contenu dans un verre d’eau, un jus de fruit, une compote ou un yaourt

Declaration 145052, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Crocus sativus L.StigmatesExtrait sec hydroalcoolique30 mg

Additives

E1204, E414

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “SAFRAN ÉQUILIBRE PREMIUM (SAFR’INSIDETM): composition and regulation”, https://compoatlas.com/en/supplements/products/145052-safran-equilibre-premium-safr-insidetm, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line